Mastiseal 2.6 g Intramammary Suspension for Cattle, Dry Cow

Riik: Suurbritannia

keel: inglise

Allikas: VMD (Veterinary Medicines Directorate)

Osta kohe

Toote omadused Toote omadused (SPC)
20-07-2021

Toimeaine:

Bismuth Subnitrate

Saadav alates:

Cross Vetpharm Group Ltd

ATC kood:

QG52X

INN (Rahvusvaheline Nimetus):

Bismuth Subnitrate

Ravimvorm:

Intramammary suspension

Retsepti tüüp:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutiline rühm:

Cattle

Terapeutiline ala:

Miscellaneous mechanical teat seal

Volitamisolek:

Expired

Loa andmise kuupäev:

2015-01-19

Toote omadused

                                Revised: May 2017
AN: 01707/2016
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Mastiseal 2.6 g Intramammary Suspension for Cattle, Dry Cow (IE, UK)
Boviseal 2.6 g Intramammary Suspension for Cattle, Dry Cow (DE, PL,
IT, NL, ES,
AT, BE, CZ, EE, EL, HU, LT, LV, PT, SK)
Boviseal Intramammary Suspension for Cattle (Dry Cow) (FR)
Boviseal vet 2.6 g Intramammary Suspension for Cattle, Dry Cow (FI)
Boviseal (DK)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4 g intramammary syringe contains:
Active substance:
Bismuth subnitrate, heavy
2.6 g
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Intramammary suspension.
Greyish white, smooth oily suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (dairy cattle at the end of lactation)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The veterinary medicinal product is indicated for the prevention of
new intramammary
infections throughout the dry period. This results in a reduction in
the incidence of
subclinical mastitis in cows at calving, and of clinical mastitis in
the dry period and the
subsequent lactation (for at least 60 days after calving).
It is recommended that the veterinary medicinal product be used as
part of a herd
approach to dry cow management and mastitis control.
4.3
CONTRAINDICATIONS
Do not use in the lactating cow.
Do not use in cases of known hypersensitivity to the active substance
or any of the
excipients.
Do not use in cows with suspected or confirmed mastitis at drying off.
See section
4.5.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Revised: May 2017
AN: 01707/2016
Page 2 of 5
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
It is good practice to observe dry cows regularly for signs of
clinical mastitis.
If a sealed quarter develops clinical mastitis the affected quarter
should be stripped
out manually before appropriate antibacterial therapy is instituted.
Cows considered likely to be free of subclinical mastitis should be
given the

                                
                                Lugege kogu dokumenti